Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Asterias Biotherapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Asterias Biotherapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Asterias Biotherapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Asterias Biotherapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Asterias Biotherapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Asterias Biotherapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Asterias Biotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Asterias Biotherapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Asterias Biotherapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 985.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Michael H. Mulroy, also known as Mike, serves as the President of Mulroy Advisors, LLC. Mr. Mulroy has been the Chief Executive Officer and President at Asterias Biotherapeutics, Inc since June 26, 2017. He has experience as a strategic planner and as legal counsel and member of a senior management team of a growing biopharmaceutical company. Mr. Mulroy has experience in corporate finance and investor relations. He served as a Senior Advisor to CamberView Partners, LLC. Mr. Mulroy served as Executive Vice President of Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc until September 2014. He served as an Executive Vice President of Strategic Affairs at Questcor Pharmaceuticals, Inc. since February 17, 2014. Mr. Mulroy served as General Counsel and Secretary of Questcor Pharmaceuticals, Inc. since January 2011 and corporate counsel since 2005. At Questcor, Mr. Mulroy served in various capacities from January 2011 to September 2014. He served as the Chief Financial Officer of Questcor Pharmaceuticals, Inc. from January 2011 to February 17, 2014; as Executive Vice President from July 31, 2013 to February 17, 2014 and Principal Accounting Officer from September 26, 2011 to February 17, 2014. He was a Partner of Stradling Yocca Carlson & Rauth, P.C since 2004. He served at Stradling Yocca from 2003 to 2011, where he represented Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an Investment Banker at Merrill Lynch and Citigroup from 1997 to 2003, where he advised healthcare companies and other clients across a range of industries in connection with corporate finance and strategic transactions. He has been an Independent Director of BioTime, Inc. since October 06, 2014. He served as Director of Asterias Biotherapeutics, Inc. from June 26, 2017 to March 8, 2019. He serves as a Director of privately-held Magtrol Inc. He serves as a Director of AgeX Therapeutics, Inc. since January 2017. He served as an Independent Director of Comarco, Inc. from July 21, 2011 to August 25, 2014. Mr. Mulroy is a Member of the State Bar of California and the Orange County Bar Association, Business Section. He is a business consultant. He earned his J.D. Degree from the University of California, Los Angeles and his B.A. in Economics from the University of Chicago.
Insufficient data for Michael to compare compensation growth.
Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Asterias Biotherapeutics management team is less than 2 years, this suggests a new team.
CEO & President
Chief Medical Officer
CFO & General Counsel
Senior Vice President of Research & Product Development
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.